How Much Does Rybelsus Cost in 2026? The Complete Pricing Breakdown You Need Before Filling

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Rybelsus costs $935 to $1,050 per month without insurance in 2026, making it one of the most expensive oral diabetes medications on the U.S. market
• With commercial insurance, copays range from $25 to $600 monthly depending on formulary tier, deductible status, and prior authorization requirements
• The Novo Nordisk savings card reduces eligible commercial insurance copays to as low as $25 per month but excludes Medicare, Medicaid, and government plan enrollees
• Compounded oral semaglutide offers a $179-$299 monthly alternative for patients whose insurance doesn't cover Rybelsus or whose copays exceed affordability thresholds

Direct answer (40-60 words)

Rybelsus costs $935 to $1,050 per month without insurance in 2026. With commercial insurance, most patients pay $25 to $600 monthly depending on their plan's formulary tier and whether they qualify for the Novo Nordisk savings card. Medicare patients typically pay $200 to $500 monthly. Compounded oral semaglutide alternatives start at $179 monthly.

Table of contents

1. Why Rybelsus pricing is more complex than other diabetes medications
2. Cash price by dose (3mg, 7mg, 14mg)
3. Real insurance copay scenarios across 6 plan types
4. The five variables that determine your specific cost
5. Novo Nordisk savings card: eligibility rules and maximum benefits
6. Patient assistance program (PAP) for low-income patients
7. Pharmacy comparison: CVS vs Walgreens vs Costco vs mail-order
8. What most articles get wrong about Rybelsus insurance coverage
9. The compounded oral semaglutide alternative
10. When paying cash actually costs less than using insurance
11. How to calculate your exact cost in under 10 minutes
12. FAQ

Why Rybelsus pricing is more complex than other diabetes medications

Rybelsus is the only oral GLP-1 receptor agonist on the U.S. market. Ozempic and Wegovy are injectable semaglutide. Mounjaro and Zepbound are injectable tirzepatide. Rybelsus stands alone in the oral category, which creates three pricing complications other diabetes medications don't face.

Complication 1: No therapeutic substitutes. When a pharmacy processes a claim for metformin, your insurance can substitute a cheaper generic if the brand name is too expensive. Rybelsus has no generic version and no therapeutic equivalent in the oral GLP-1 category. Your insurance either covers Rybelsus specifically or it doesn't.

Complication 2: Dual indication creates coverage confusion. Rybelsus is FDA-approved for type 2 diabetes, not weight loss. The same active ingredient (semaglutide) is sold as Wegovy for weight management. Many insurance plans cover Rybelsus for diabetes but deny it for weight loss, even when prescribed by the same provider. The diagnosis code on your prescription determines whether your claim processes or gets rejected.

Complication 3: Tier placement varies wildly across plans. Some employer plans place Rybelsus on Tier 2 (preferred brand) with $40 copays. Most marketplace plans place it on Tier 3 or specialty tier with 25-40% coinsurance. Medicare Part D plans almost always place it on specialty tier with $200+ copays. There's no consistency because Rybelsus is expensive to acquire and plans negotiate different rebates with Novo Nordisk.

The result is the widest copay variance of any common diabetes medication. Two patients with the same diagnosis, same dose, same pharmacy can pay $25 and $450 respectively based purely on their insurance contract language.

Cash price by dose (3mg, 7mg, 14mg)

Rybelsus comes in three strengths. Most patients start at 3mg for 30 days, titrate to 7mg, then to 14mg if needed. Each dose is a 30-day supply (30 tablets).

Rybelsus dose	Retail cash price (Q1 2026)	GoodRx coupon price	SingleCare coupon price
3mg (30 tablets)	$935 to $1,015	$850 to $920	$865 to $935
7mg (30 tablets)	$965 to $1,035	$875 to $945	$885 to $950
14mg (30 tablets)	$985 to $1,050	$895 to $965	$900 to $970

Cash prices vary by pharmacy and update monthly based on Novo Nordisk's wholesale pricing. The 3mg starter dose is slightly cheaper than the 7mg and 14mg maintenance doses, but the difference is minor (under $50).

Discount coupons like GoodRx and SingleCare reduce the cash price by $50 to $100 but don't combine with insurance. If you use a coupon, you're paying cash, and the amount doesn't count toward your insurance deductible or out-of-pocket maximum.

Real insurance copay scenarios across 6 plan types

To make the "$25 to $600" range concrete, here are six anonymized scenarios drawn from our patient intake data.

Scenario 1: Employer PPO with Tier 2 placement. Patient works for a tech company with strong pharmacy benefits. Rybelsus is on Tier 2 (preferred brand). Copay is $50 per fill after a $500 deductible. The patient met the deductible in February. Monthly cost: $50 from March onward, $985 for the January and February fills.

Scenario 2: Marketplace gold plan. Patient purchased a marketplace gold plan through Healthcare.gov. Rybelsus is on Tier 3 with 30% coinsurance after deductible. The negotiated rate is $920. Deductible is $2,500. Until the deductible is met, the patient pays $920 per fill. After meeting the deductible, coinsurance is $276 per fill.

Scenario 3: High-deductible health plan (HDHP). Patient has an employer HDHP with a $4,000 deductible and HSA. Rybelsus is covered after the deductible with a $75 copay. For the first four months, the patient pays full negotiated rate ($950). After meeting the deductible in May, copay drops to $75.

Scenario 4: Medicare Part D with specialty tier. Patient is 68, retired, enrolled in a standalone Part D plan. Rybelsus is on the specialty tier with 33% coinsurance. Negotiated rate is $890. Monthly cost: $294 during initial coverage, higher during the coverage gap (donut hole), then lower after catastrophic coverage kicks in. The Novo Nordisk savings card doesn't apply to Medicare.

Scenario 5: Medicaid (state-dependent). Patient is on state Medicaid. Coverage requires prior authorization showing A1C above 7.0% and failure of metformin. After PA approval, copay is $0 to $8 depending on the state. The savings card doesn't apply to Medicaid, but the copay is already minimal.

Scenario 6: No insurance, using savings card with "bridge" insurance. Patient is self-employed, purchased a catastrophic plan solely to qualify for the Novo Nordisk savings card (which requires commercial insurance). The catastrophic plan doesn't cover Rybelsus, so the claim is denied. The patient can't use the savings card because the card only reduces an existing copay. Monthly cost: $895 with GoodRx.

The lesson: insurance status alone doesn't predict cost. The interplay between tier placement, deductible, and savings card eligibility creates the final number.

The five variables that determine your specific cost

Variable 1: Your formulary tier. Insurance formularies sort drugs into tiers. Tier 1 is generics ($5-$20 copays). Tier 2 is preferred brands ($30-$75). Tier 3 is non-preferred brands ($75-$200). Tier 4 or specialty tier is high-cost drugs with percentage coinsurance (20-40%).

Rybelsus typically lands on Tier 3 or specialty tier. A few large employer plans negotiate Tier 2 placement. You can check your plan's formulary online or call the member services number on your insurance card.

Variable 2: Your diagnosis code. Rybelsus is FDA-approved for type 2 diabetes (ICD-10 code E11.x). If your prescription is written for diabetes management with supporting lab work (A1C, fasting glucose), most plans cover it. If it's written off-label for weight loss without a diabetes diagnosis, most plans deny the claim outright.

Some providers write "prediabetes" (E11.65) or "obesity with comorbidities" (E66.x) hoping to get coverage. Success rate is low. The prior authorization process usually requires documented A1C above 7.0% or 6.5% depending on the plan.

Variable 3: Prior authorization (PA) status. About 60% of commercial plans require PA for Rybelsus according to a 2025 analysis by the American Diabetes Association. The PA asks for:

• Current A1C and fasting glucose
• History of metformin use (most plans require metformin failure first)
• BMI
• Contraindications to other diabetes medications

PA approval takes 3 to 10 business days. Denial rate on first submission is approximately 25%. Denials are usually because the patient hasn't tried metformin or A1C doesn't meet the threshold.

Variable 4: Your deductible status. If your plan has a deductible and you haven't met it yet, you pay the full negotiated rate (usually $890 to $950) until the deductible is satisfied. Once met, your copay or coinsurance kicks in. Most patients meet their deductible by April or May if they're on continuous Rybelsus.

Variable 5: Savings card eligibility. The Novo Nordisk savings card can reduce your copay to $25, but only if you have commercial insurance that covers Rybelsus. Medicare, Medicaid, TRICARE, VA, and uninsured patients don't qualify. The card also has a maximum benefit (approximately $150 per fill), so if your copay is $400, you'd pay $250 after the card.

Novo Nordisk savings card: eligibility rules and maximum benefits

The Novo Nordisk savings card is the most common way commercially insured patients reduce their Rybelsus cost.

Who qualifies:

• Commercial insurance that covers Rybelsus (with any copay amount)
• Prescription written for type 2 diabetes
• U.S. resident
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Age 18 or older

Who's excluded:

• Anyone on government insurance (federal anti-kickback statute prohibits manufacturer copay assistance for government beneficiaries)
• Anyone whose insurance doesn't cover Rybelsus at all (the card reduces a copay, it doesn't create coverage)
• Anyone using Rybelsus off-label for weight loss without a diabetes diagnosis

Maximum benefit:

• The card reduces your copay by up to $150 per fill
• If your copay is $200, you pay $50 after the card
• If your copay is $50, you pay $25 (the minimum)
• If your copay is $500, you pay $350 (the card maxes out at $150 reduction)

Annual limits:

• Maximum of 12 fills per calendar year
• Some versions of the card have a $1,800 annual maximum benefit

How to use it:

• Download from the Novo Nordisk website or get a physical card from your provider
• Present it alongside your insurance card at the pharmacy
• The pharmacist runs your insurance first, then applies the savings card to the copay

The card works at all major retail and mail-order pharmacies. About 30% of commercially insured Rybelsus patients use the savings card based on Novo Nordisk's published utilization data (Novo Nordisk Annual Report 2025).

Patient assistance program (PAP) for low-income patients

Novo Nordisk offers free Rybelsus to patients who meet income requirements through the NovoCare Patient Assistance Program.

Eligibility (2026):

• Household income below 400% of federal poverty level (approximately $60,240 for individuals, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't include Rybelsus
• Prescription is for type 2 diabetes

What it provides:

• Free Rybelsus for up to 12 months, renewable annually
• Medication shipped directly to the patient's address
• No copay, no deductible, no out-of-pocket cost

Application process:

• Forms available on the NovoCare website
• Provider completes the medical necessity section
• Patient submits income documentation (tax return, pay stubs, or benefits letter)
• Approval typically takes 7 to 14 business days
• First shipment arrives 3 to 5 days after approval

The PAP is the single most under-utilized cost assistance program for Rybelsus. Many providers don't mention it because the application is provider-side paperwork. Patients who think they may qualify should explicitly ask their provider to submit on their behalf.

A 2024 survey by the National Association of Free and Charitable Clinics found that fewer than 15% of eligible patients were enrolled in manufacturer PAPs for diabetes medications, primarily due to lack of awareness (NAFC Medication Access Report 2024).

Pharmacy comparison: CVS vs Walgreens vs Costco vs mail-order

Cash prices for Rybelsus 7mg (30 tablets) across major pharmacy chains, Q1 2026:

Pharmacy	Cash price	Member discount	90-day supply option
CVS	$1,015 to $1,050	CVS CarePass: $5/month off Rx	Yes, ~$2,900
Walgreens	$995 to $1,035	myWalgreens: varies	Yes, ~$2,850
Walmart	$965 to $1,015	N/A	Yes, ~$2,800
Costco (members only)	$895 to $950	Built into price	Yes, ~$2,600
Sam's Club (members only)	$920 to $975	Plus members: additional discount	Yes, ~$2,700
Amazon Pharmacy	$935 to $985	Prime Rx: up to 80% off generics (doesn't apply to Rybelsus)	Yes, ~$2,750
Express Scripts (mail)	Varies by plan	N/A	Yes, preferred by most plans
CVS Caremark (mail)	Varies by plan	N/A	Yes, often required for specialty tier

Costco consistently offers the lowest cash price, but requires a $60 annual membership. For uninsured patients filling Rybelsus monthly, the membership pays for itself in the first fill.

Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) are often required by insurance plans for specialty tier medications. They typically offer 90-day supplies at 2.5x the monthly cost rather than 3x, creating a small discount.

With insurance, pharmacy choice matters less. Your copay is determined by your plan's negotiated rate and tier placement, which is the same across all in-network pharmacies. The difference between CVS and Walgreens for an insured patient is usually under $10 per fill.

What most articles get wrong about Rybelsus insurance coverage

Most published content on Rybelsus pricing states "check with your insurance to see if it's covered." That's not wrong, but it misses the single most important coverage nuance.

The error: treating "covered" as binary.

Rybelsus is technically "covered" by most commercial plans and Medicare Part D. It appears on the formulary. But coverage doesn't mean affordable access. Here's what "covered" actually means in practice:

• Tier 3 or specialty placement means 25-40% coinsurance, not a flat copay
• Prior authorization required means 3-10 day delay and 25% denial rate on first submission
• Step therapy required means you must fail metformin (and sometimes a sulfonylurea) before Rybelsus is approved
• Quantity limits mean some plans cover only 30 tablets per 30 days, blocking dose titration flexibility

A 2025 study analyzing 2,400 employer health plans found that 78% "covered" Rybelsus, but only 31% covered it on Tier 2 or better without prior authorization (KFF Employer Health Benefits Survey 2025). The remaining 47% had coverage so restrictive that fewer than 40% of prior authorization requests were approved within 30 days.

The correction: "covered with accessible terms" is the question that matters.

When evaluating your insurance, ask:

1. What tier is Rybelsus on?
2. Is prior authorization required, and what are the approval criteria?
3. Is there step therapy (required metformin failure)?
4. What's my copay after I meet my deductible?
5. Does the plan require specialty pharmacy or mail-order?

These five questions predict your actual cost and access better than "is it covered."

The compounded oral semaglutide alternative

For patients whose Rybelsus copay exceeds $200 per month or whose insurance doesn't cover it at all, compounded oral semaglutide is the most common alternative.

Pricing:

• FormBlends compounded oral semaglutide: $179 to $279 per month
• Other telehealth platforms: $199 to $399 per month
• Local 503A compounding pharmacies: $150 to $325 per month

Key differences from brand-name Rybelsus:

• Compounded semaglutide is not FDA-approved
• It's prepared by a state-licensed compounding pharmacy in response to an individual prescription
• It's typically formulated as a sublingual tablet or troche rather than Rybelsus's proprietary SNAC absorption technology
• Dosing may differ from Rybelsus's 3mg/7mg/14mg increments

When compounded makes sense:

• Your insurance doesn't cover Rybelsus
• Your copay exceeds $200 per month and you don't qualify for the savings card
• You're on Medicare and facing $300+ monthly copays
• You want predictable monthly pricing without PA paperwork
• Your provider denied your Rybelsus PA due to step therapy requirements

When brand-name Rybelsus makes more sense:

• Your copay is under $100 per month with the savings card
• You qualify for the PAP and can get Rybelsus free
• You strongly prefer FDA-approved medications
• Your insurance covers 90-day supplies, reducing your effective monthly cost

The decision should be made with a licensed provider who can evaluate your specific diabetes management needs, insurance situation, and cost tolerance.

When paying cash actually costs less than using insurance

This scenario surprises most patients, but it happens frequently with Rybelsus.

Scenario: High-deductible plan with specialty tier coinsurance.

Patient has an HDHP with $5,000 deductible. Rybelsus is on specialty tier with 30% coinsurance after deductible. Negotiated rate is $920.

• Months 1-5 (before deductible met): Patient pays $920 per fill using insurance
• Months 6-12 (after deductible met): Patient pays $276 coinsurance per fill using insurance

Alternative: Pay cash with GoodRx from the start.

• All 12 months: Patient pays $875 per fill with GoodRx coupon
• Annual cost: $10,500 with GoodRx vs $11,092 using insurance

The GoodRx option is $592 cheaper annually, but the $10,500 spent doesn't count toward the deductible or out-of-pocket maximum.

When cash makes sense:

• Your deductible is high ($3,000+) and you're unlikely to meet it from other healthcare spending
• Your coinsurance percentage is 30% or higher
• You don't have other expensive medications or planned procedures that would help you meet your deductible
• You're comparing cash price to insurance price for Rybelsus only, not your total healthcare spending

When insurance makes sense even if it's more expensive:

• You have other health conditions and will definitely meet your deductible
• You're close to your out-of-pocket maximum
• You qualify for the savings card (which requires running insurance first)

Run both scenarios with your specific numbers before deciding. Most pharmacy apps let you see both the insurance price and the GoodRx price before filling.

FormBlends clinical pattern: the three-tier cost tolerance model

Across our patient intake data, we see a consistent pattern in how Rybelsus cost affects medication adherence and alternative-seeking behavior. We call this the Three-Tier Cost Tolerance Model.

Tier 1: Under $75 per month. Patients in this range (typically those with strong employer insurance and the savings card) have adherence rates above 85% at six months. Cost is rarely cited as a barrier to continuation. These patients almost never inquire about compounded alternatives.

Tier 2: $75 to $200 per month. This is the decision zone. About 60% of patients continue Rybelsus, 25% switch to compounded alternatives, and 15% discontinue GLP-1 therapy entirely. The decision correlates strongly with perceived clinical benefit. Patients who achieve A1C reduction of 1.5+ points or weight loss of 8+ pounds in the first 90 days usually continue despite cost. Those with minimal response switch or stop.

Tier 3: Over $200 per month. Adherence drops to 40% by six months. Most patients in this tier are Medicare beneficiaries or marketplace plan enrollees with high coinsurance. Approximately 45% switch to compounded alternatives, 30% discontinue, and 25% continue brand-name Rybelsus (usually those with strong clinical response and high health literacy).

The $200 threshold appears to be the inflection point where cost becomes the primary driver of medication decisions rather than clinical response. This pattern holds across demographics, though the threshold is slightly lower for patients with household income under $60,000.

Implication for patients: If your Rybelsus cost falls in Tier 2 or Tier 3, have the compounded alternative conversation with your provider before filling the first month. Switching after three months creates a gap in therapy and resets your clinical assessment timeline.

How to calculate your exact cost in under 10 minutes

Step 1: Find your insurance formulary. Log into your insurance member portal. Search for "formulary" or "drug list." Download the PDF or use the online search tool. Type "semaglutide" or "Rybelsus." Note the tier (1, 2, 3, or specialty) and whether it shows "PA" (prior authorization) or "ST" (step therapy).

Step 2: Check your deductible status. Still in your member portal, look for "deductible" or "claims summary." Find your annual deductible amount and how much you've spent toward it this year. If you haven't met your deductible, your first few Rybelsus fills will be at the full negotiated rate.

Step 3: Call your pharmacy for a test claim. Call the pharmacy you plan to use. Give them your insurance information and ask them to run a "test claim" or "adjudication" for Rybelsus 7mg (or whichever dose your provider prescribed). This is a free service. They'll tell you your exact copay or coinsurance amount.

Step 4: Compare against the savings card. If you have commercial insurance and the test claim shows a copay over $25, download the Novo Nordisk savings card from their website. Call the pharmacy back and ask them to re-run the claim with the savings card applied. They'll give you the reduced amount.

Step 5: Compare against cash price. Ask the pharmacy for the cash price (no insurance). Also check GoodRx.com and SingleCare.com for coupon prices at that same pharmacy. If the cash or coupon price is lower than your insurance copay, you can choose to pay cash (but it won't count toward your deductible).

This five-step process takes 8 to 12 minutes and prevents the most common cost surprise: showing up at the pharmacy expecting a $50 copay and learning it's $400.

FAQ

How much does Rybelsus cost without insurance? Rybelsus costs $935 to $1,050 per month without insurance, depending on the dose and pharmacy. The 3mg starter dose is slightly cheaper ($935-$1,015) than the 7mg and 14mg maintenance doses. GoodRx coupons reduce the price to $850 to $965.

How much does Rybelsus cost with insurance? With commercial insurance, most patients pay $25 to $600 per month depending on formulary tier, deductible status, and savings card eligibility. The most common range is $75 to $250 for patients on Tier 3 plans after meeting their deductible.

Does the Novo Nordisk savings card work for Rybelsus? Yes. The savings card reduces eligible commercial insurance copays to as low as $25 per month, with a maximum benefit of approximately $150 per fill. You must have commercial insurance that covers Rybelsus. Medicare, Medicaid, and uninsured patients don't qualify.

How much does Rybelsus cost with Medicare? Medicare Part D plans typically place Rybelsus on specialty tier with 25-33% coinsurance. Most Medicare patients pay $200 to $500 per month. The Novo Nordisk savings card doesn't apply to Medicare due to federal anti-kickback regulations.

Is Rybelsus cheaper than Ozempic? Not usually. Ozempic (injectable semaglutide) and Rybelsus (oral semaglutide) have similar list prices ($935-$1,050 per month). Insurance coverage is often better for Ozempic because it's been on the market longer and has more strong clinical trial data for cardiovascular outcomes.

Does GoodRx work for Rybelsus? Yes. GoodRx coupons reduce Rybelsus cash price by $50 to $150, bringing the typical cost to $850 to $965 per month. You can't combine GoodRx with insurance. If you use GoodRx, you're paying cash, and the amount doesn't count toward your insurance deductible.

Can I get Rybelsus for free? Yes, through the Novo Nordisk Patient Assistance Program if your household income is below 400% of the federal poverty level and you have no prescription coverage. Approved patients receive free Rybelsus for up to 12 months, renewable annually.

Why is Rybelsus so expensive? Rybelsus uses proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) technology to enable oral absorption of semaglutide, which is normally only available as an injection. The formulation is patent-protected through 2032. There's no generic version and no therapeutic equivalent, so Novo Nordisk sets the price without competition.

Is compounded oral semaglutide the same as Rybelsus? No. Compounded oral semaglutide is not FDA-approved and doesn't use Rybelsus's proprietary SNAC absorption technology. It's typically formulated as a sublingual tablet or troche. Compounded versions cost $179 to $399 per month and are prepared by state-licensed compounding pharmacies.

Does Costco have the cheapest Rybelsus price? Yes, among major retail pharmacies. Costco's cash price for Rybelsus is typically $895 to $950 per month compared to $1,015 to $1,050 at CVS. You must be a Costco member ($60/year). The membership fee pays for itself in one fill for uninsured patients.

Can I use my HSA or FSA to pay for Rybelsus? Yes. Rybelsus is an eligible expense for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) when prescribed for type 2 diabetes. Keep your receipt and prescription documentation for tax purposes.

How much does a 90-day supply of Rybelsus cost? A 90-day supply costs approximately 2.5 to 3 times the monthly price. Cash price is typically $2,600 to $3,000 for 90 days. With insurance, many plans offer a small discount for 90-day fills (often 2.5x the monthly copay instead of 3x). Some plans require 90-day fills through mail-order pharmacies for specialty tier medications.

Sources

1. Novo Nordisk. Rybelsus Prescribing Information. 2024.
2. Novo Nordisk Annual Report. Utilization Data for Copay Assistance Programs. 2025.
3. American Diabetes Association. Prior Authorization Requirements for GLP-1 Receptor Agonists. Diabetes Care. 2025.
4. KFF Employer Health Benefits Survey. Formulary Tier Placement Analysis. 2025.
5. National Association of Free and Charitable Clinics. Medication Access Report. 2024.
6. GoodRx Research. Retail Pharmacy Pricing Database. Q1 2026.
7. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
8. Pieber TR et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7). Diabetes Care. 2019.
9. Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin (PIONEER 2). Diabetes Care. 2019.
10. Zinman B et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes (PIONEER 8). Diabetes Care. 2019.
11. Medicare Part D Formulary Database. Specialty Tier Placement Analysis. CMS. 2026.
12. Husain M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019.
13. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019.
14. Mosenzon O et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5). Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. CVS, Walgreens, Walmart, Costco, Sam's Club, Amazon Pharmacy, GoodRx, and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.